Hepcidin and GDF15 in anemia of multiple myeloma

Robert A, Kyleand S, Rajkumar V, et al. Multiple myeloma. Blood. 2008;111:2962–72.

Caravita T, Siniscalchi A, Montanaro M, et al. High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients. Int J Hematol. 2009;90:270–2.

Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia. Med Hypotheses. 2006;66:352–4.

Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma. 2003;4(Suppl 1):S23–9.

Silvestris F, Tucci M, Quatraro C, et al. Recent advances in understanding the pathogenesis of anemia in multiple myeloma. Int J Hematol. 2003;78:121–5.

Goodnough LT. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol. 2007;35:167–72.

Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–101.

Liu X, Xie W, Liu P, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia–reperfusion. Life Sci. 2006;78:2255–64.

Peyssonnaux C, Zinkernagel AS, Datta V, et al. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood. 2006;107:3727–32.

Theurl I, Theurl M, Seifert M, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111:2392–9.

Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–7.

Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14:3262–7.

Birgegård G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol. 2006;77:378–86.

Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood. 2003;101:2461–3.

Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Investig. 2004;113:1271–6.

Truksa J, Peng H, Lee P, Beutler E. Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol. 2007;139:138–47.

Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116:3635–44.

Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008;112:1503–9.

Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41:478–81.

Andriopoulos B, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41:482–7.

Katodritou E, Ganz T, Terpos E, et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. Am J Hematol. 2009;84:524–6.

Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204–9.

Tarkun P, Birtas Atesoglu E, Mehtap O, et al. Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients. Acta Haematol. 2013;131:173–8.

Corre J, Labat E, Espagnolle N, et al. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res. 2012;72:1395–406.

Tanno T, Lim Y, Wang Q, et al. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood. 2014;123:725–33.

Tamary H, Shalev H, Perez-Avraham G. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood. 2008;112:5241–4.

Aizawa S, Harada T, Kanbe E, et al. Ineffective erythropoiesis in mutant mice with deficient pyruvate kinase activity. Exp Hematol. 2005;33:1292–8.

Kempf T, Horn-Wichmann R, Brabant G, et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem. 2007;53:284–91.

Akiyama M, Okano K, Fukada Y, et al. Macrophage inhibitory cytokine MIC-1 is upregulated by short-wavelength light in cultured normal human dermal fibroblasts. FEBS Lett. 2009;583:933–7.

Ago T, Kuroda J, Pain J, et al. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res. 2010;106:1253–64.

Léon K, Grace J, Elizabeta N, et al. The erythroid factor erythroferrone and its role in iron homeostasis. Blood. 2013;122:21–4.